Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
871.96
+6.96 (+0.80%)
Streaming Delayed Price
Updated: 1:33 PM EST, Feb 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Today 12:35 EST
Via
Benzinga
Behind the Scenes of Eli Lilly's Latest Options Trends
Today 12:15 EST
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 11, 2025
Via
Benzinga
Healthcare And Biotech Playbook As Disruption Gathers Force
February 10, 2025
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
February 10, 2025
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.
Via
Benzinga
2 Growth Stocks to Buy Hand Over Fist in February
February 09, 2025
Via
The Motley Fool
Is Novo Nordisk Stock a Buy Now?
February 08, 2025
Via
The Motley Fool
Looking Into Eli Lilly's Recent Short Interest
February 07, 2025
Via
Benzinga
5 ETFs That Beat Market Turmoil With Gains Last Week
February 10, 2025
Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs.
Via
Benzinga
Topics
ETFs
Economy
Exposures
Interest Rates
These Stocks Missed on Earnings, But Will Rebound Next Quarter
February 10, 2025
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year
Via
MarketBeat
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
February 10, 2025
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system.
Via
Stocktwits
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
February 08, 2025
Via
The Motley Fool
Market Monitor February 6th
February 07, 2025
Market Recap: Wall Street Gains, Amazon Slips, and U.S. Job Growth Slows
Via
Chartmill
A Closer Look at Eli Lilly's Options Market Dynamics
February 06, 2025
Via
Benzinga
Why Eli Lilly Stock Popped on Thursday
February 06, 2025
Via
The Motley Fool
How To Ride The Market’s “Great Risk Rollercoaster”
February 07, 2025
This market is trading in an extremely tight range and has been for a long time now. It’s a market desperate for a catalyst just isn’t finding any - not in data, not in news, not in Tweets.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Magnificent Seven Slip, Inflation Fears Grip Consumers, Gold Hits Record Highs: This Week In The Markets
February 07, 2025
Wall Street cautious on mixed earnings, macroeconomic data, and geopolitical developments. Gold hits record high while Ford's outlook disappoints.Wall St cautious due to mixed earnings, data &...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
February 07, 2025
Shares rocketed on Friday, but the company might not be out of hot water yet.
Via
Investor's Business Daily
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
February 07, 2025
On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
Via
Benzinga
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
February 07, 2025
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also...
Via
Stocktwits
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript
February 06, 2025
LLY earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
February 06, 2025
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Trump Focused On 10-Year Yield And Not On The Fed, Slower AI Growth Fears Weigh On Arm Stock
February 06, 2025
To gain an edge, this is what you need to know today.
Via
Benzinga
Topics
Artificial Intelligence
Economy
Government
Exposures
Artificial Intelligence
Interest Rates
Political
The 9 Best Stocks to Buy Now in February (2025)
February 06, 2025
Via
The Motley Fool
In 2025, the pharmaceutical industry is ripe for M&A
February 06, 2025
Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment for mergers and acquisitions
Via
Equities.com
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat
February 06, 2025
Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.
Via
Stocktwits
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
February 06, 2025
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.
Via
Investor's Business Daily
Exposures
Product Safety
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
February 06, 2025
Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.
Via
Benzinga
Eli Lilly’s Q4 2024 Revenue Surges By 45% To $13.53 Billion
February 06, 2025
Eli Lilly and Company reported a robust revenue growth of 45% in Q4 2024, reaching $13.53 billion, driven by increased volume from key products.
Via
Talk Markets
Topics
Stocks / Equities
Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss
February 06, 2025
Eli Lilly earnings beat Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.